Seeing Is Believing
Currently out of the existing stock ratings of Andrew Berens, 153 are a BUY (69.23%), 48 are a HOLD (21.72%), 20 are a SELL (9.05%).
Analyst Andrew Berens, currently employed carries an average stock price target met ratio of 53.74% that have a potential upside of 28.38% achieved within 210 days. Previously, Andrew Berens worked at LEERINK.
Andrew Berens’s has documented 433 price targets and ratings displayed on 38 stocks. The coverage was on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on BPMC, Blueprint Medicines Corp at 06-May-2024.
Analyst best performing recommendations are on ELEV (ELEVATION ONCOLOGY).
The best stock recommendation documented was for ELEV (ELEVATION ONCOLOGY) at 1/9/2023. The price target of $1 was fulfilled within 3 days with a profit of $0.2 (25%) receiving and performance score of 83.33.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
46
$-0.61 (-1.31%)
30
1 months 13 days ago
4/4 (100%)
$-0.77 (-1.65%)
169
Hold
53
$6.39 (13.71%)
33
1 months 22 days ago
7/8 (87.5%)
$5.65 (11.93%)
165
Buy
42
$-4.61 (-9.89%)
67
1 years 29 days ago
6/12 (50%)
$13.87 (49.31%)
234
Buy
38
$-8.61 (-18.47%)
40
1 years 29 days ago
2/4 (50%)
$9.87 (35.09%)
366
Buy
37
$-9.61 (-20.62%)
33
1 years 11 months 21 days ago
8/11 (72.73%)
$7.26 (24.41%)
250
Which stock is Andrew Berens is most bullish on?
What Year was the first public recommendation made by Andrew Berens?